by
Gus Iversen, Editor in Chief | November 25, 2025
ARC Innovation at Sheba Medical Center and the Icahn School of Medicine at Mount Sinai have entered a three-year partnership with NVIDIA to apply large language model (LLM) technology to the human genome, aiming to better understand the vast majority of DNA sequences that remain poorly characterized.
The initiative brings together genomic data sets, clinical knowledge, and AI tools to explore the 98% of the genome that does not encode proteins but is increasingly understood to play regulatory and functional roles in human biology. The collaboration will focus on building a genomic foundation model (gFM) that could help researchers identify genetic variations linked to disease risk and treatment response.
Prof. Gidi Rechavi, who leads cancer research efforts at the Ramat Gan, Israel-based Sheba Medical Center and helped initiate the project, said, “While approximately two percent of the human genome has been thoroughly characterized, the remaining 98 percent, which was once labeled junk DNA, is increasingly recognized as containing critical regulatory and functional elements.”
Ad Statistics
Times Displayed: 344592
Times Visited: 21056 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
NVIDIA, based in Santa Clara, California, is contributing its AI infrastructure and expertise to support the project. According to the company’s applied AI architecture leads, Dr. Nati Daniel and Dr. Yoli Shavit, “The development of a state-of-the-art Genomic Foundation Model (gFM), brings together clinicians, geneticists, bioinformaticians, and AI researchers to tackle one of science’s greatest challenges with NVIDIA’s full-stack AI platform.”
At Mount Sinai, the effort is aligned with the institution’s Million Health Discoveries Program, led by Dr. Alexander Charney. He described the collaboration as “an important step toward a future where every person can benefit from the power of whole genome sequencing.”
The joint platform is expected to support global scientific collaboration by enabling deeper analysis of genomic regions associated with complex diseases. Research teams across all three institutions have already started foundational work.
The project will be co-led by Sheba’s newly established AI Center and Mount Sinai’s Charles Bronfman Institute for Personalized Medicine.
